Kura Oncology (KURA) Stock Analysis

What Kura Oncology does

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Key metrics

ETFs linked to KURA

Broad-market and Healthcare sector ETFs an investor holding Kura Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KURA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Kura Oncology?

Kura Oncology trades under the ticker KURA on NASDAQ.

Which exchange is KURA listed on?

KURA is listed on NASDAQ.

What sector does Kura Oncology operate in?

Kura Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KURA in a portfolio?

PortView shows KURA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.